Xiansheng pharmaceutical and Shiguibao to develop new rheumatoid arthritis drug orencia

On July 2, Xiansheng pharmaceutical and BMS announced at their long-term R & D strategic cooperation ceremony that they would jointly develop in China the subcutaneous injection type of orencia, a biological agent of BMS for the treatment of rheumatoid arthritis This drug is the latest heavyweight product of BMS In 2011, the global sales exceeded 1 billion yuan, and the latest sales last year was about 1.2 billion yuan This is the third R & D cooperation between the two sides since 2010 in the field of anti-tumor and cardiovascular compounds Xiansheng pharmaceutical and Bristol Myers Squibb recently held a long-term R & D strategic cooperation ceremony in Nanjing, announcing that the two sides will further continue their partnership since 2010, and jointly develop and market the subcutaneous injection type of the biological agent orencia, Bristol Myers Squibb used to treat rheumatoid arthritis, in China Previously, the hypodermic injection type of orencia has been approved for listing in the United States, Europe and Japan respectively In this long-term R & D strategic cooperation, the two sides agreed that Xiansheng pharmaceutical will be responsible for the R & D of orencia injection in China and before the approval Once approved, the two sides will be jointly responsible for the listing of orencia in China, and jointly undertake investment and share profits If the R & D is successful, orencia will become the first biological preparation product introduced by Bristol Myers Squibb in the field of rheumatism in China The experience and investment of Xiansheng pharmaceutical in the field of rheumatoid arthritis will also benefit the development of orencia in China At present, there are about 5 million patients suffering from various kinds of rheumatism in China, and only about 210000 people have been effectively diagnosed and treated The temptation of low medical treatment rate and large market space has attracted major pharmaceutical companies to join in the fight "ABP has reached the benchmark of super product since it was launched in 2006, and will become the largest product of BMS in the world in the next few years The introduction of this important product into China is also an extremely important task for the company since last year " Said Xu Fang, vice president of BMS Yin Xiaojin, vice president of Xiansheng pharmaceutical, said the product is expected to be available in China in 2018 "Two to three years of complete clinical trials are required before entering China, and then registration and approval are required Therefore, the current schedule is subject to China's strict drug market access mechanism." It is reported that the hypodermic injection type of orencia has been listed in overseas markets such as the United States, Europe and Japan This time, BMS deliberately abandoned its own R & D and introduction mode, and joined hands with local enterprises to pioneer the pharmaceutical industry The purpose of accelerating the introduction as far as possible is very clear In this strategic cooperation, Xiansheng will be responsible for the approval of the drug in China and the R & D before approval After passing the examination and approval, both parties will be jointly responsible for the listing of the drug in China and share the profits Some insiders pointed out that the deeper reason for the cooperation between the two sides lies in that all the world's famous pharmaceutical enterprises have new drug layout in this field, and China's new drug approval takes a long time If they miss the time window, they will lose a lot in China, the second largest pharmaceutical market in the world The cooperation between pioneer pharmaceutical and Bristol Myers Squibb has a solid foundation In November 2010 and December 2011, we conducted two R & D cooperation in the field of tumor and cardiovascular respectively The two companies have worked together for three times If the R & D is successful, orencia will become the first biopharmaceutical product of Bristol Myers Squibb listed in China The experience and investment of Xiansheng pharmaceutical in the field of rheumatoid arthritis will also benefit the development of orencia in China, so as to benefit the vast number of rheumatoid patients in China more quickly Previously, orencia subcutaneous injection has been successively sold in the rheumatoid arthritis market in the United States, Europe and Japan It is mainly applicable to adult patients with moderate and severe active rheumatoid arthritis, which can delay the process of structural damage caused by the disease, improve the body function of patients, and reduce relevant signs and symptoms The joint research of many scholars shows that more patients with rheumatoid arthritis can achieve disease relief or the disease is in a low level of activity after the treatment with abamiprin and methotrexate This supports the use of abacept as a first-line biological agent in combination with DMARDs in the treatment of early rheumatoid arthritis Since its launch in 2006, orencia has benefited millions of patients worldwide with its unique mechanism and outstanding clinical effect In 2012, the global sales volume was nearly US $1.2 billion, making it a blockbuster drug.